Core Insights - Firefly Neuroscience, Inc. reported significant financial growth in Q3-2025, with revenues increasing over tenfold year-over-year and 30% sequentially, primarily due to the acquisition of Evoke Neuroscience [4][7] - The company successfully integrated the Evoke business, leading to a 10.9% increase in EEG/ERP scan volumes quarter-over-quarter [3][7] - Operating expenses decreased by 35% year-over-year, contributing to a reduced net loss of $2.6 million, a 38% improvement compared to the same period in 2024 [5][6][7] Financial Performance - Q3-2025 revenue reached $388,000, up from $33,000 in Q3-2024, and a sequential increase from $299,000 in Q2-2025 [4][7] - Total operating expenses for Q3-2025 were approximately $2.8 million, down from $4.3 million in the prior year [5][7] - The net loss for Q3-2025 was approximately $2.6 million, or $0.20 per share, compared to a net loss of $4.3 million, or $0.61 per share, in Q3-2024 [6][7] Business Developments - The company is focused on executing its commercial growth strategy while leveraging NVIDIA's advanced software for developing EEG/ERP-based models of the human brain [3] - Firefly launched the 'CLEAR' platform for EEG data quality enhancement, developed using NVIDIA's L40S GPU [7] - A partnership with HealingMaps was established to provide cognitive electrophysiology analytics to over 2,500 clinics across North America [7] Cash Position - As of the end of Q3-2025, Firefly had cash reserves of $4.3 million [8]

Core Insights - Firefly Neuroscience has launched its new 'CLEAR' Platform, which enhances EEG data quality and processing speed, utilizing NVIDIA's L40S GPU technology [1][3] - The CLEAR Platform significantly improves the reliability of EEG recordings by reducing noise and artifacts, enabling better detection of neural biomarkers for neurological and psychiatric conditions [2][4] - The platform achieves a 60-80% improvement in processing times, leveraging advanced signal processing and machine learning techniques [3][4] Company Overview - Firefly Neuroscience is focused on developing AI-driven solutions to improve brain health outcomes for patients with neurological and mental disorders [5][6] - The company has built a comprehensive database of brain wave tests over the past 15 years, securing patent protection and achieving FDA clearance for its Brain Network Analytics (BNA™) technology [5][6] - BNA™ technology aims to enhance diagnostic and treatment monitoring methods for various conditions, including depression, dementia, and ADHD [5][6]

Core Insights - Firefly Neuroscience has launched its new 'CLEAR' Platform, which enhances EEG data quality and processing speed, utilizing NVIDIA's L40S GPU technology [1][3] - The CLEAR Platform significantly improves the reliability of EEG recordings, enabling better detection of neural biomarkers for neurological and psychiatric conditions [2][4] - The company aims to leverage the CLEAR Platform as a key component of its growth strategy, focusing on transforming neuroscience and clinical development through AI and EEG technology [4][5] Company Overview - Firefly Neuroscience, Inc. is an AI company dedicated to improving brain health outcomes for patients with neurological and mental disorders [5] - The company has developed the FDA-510(k) cleared Brain Network Analytics (BNA™) technology, which enhances diagnostic and treatment monitoring for various conditions [5][6] - Firefly has built a comprehensive database of over 17,000 standardized EEGs, which supports its innovative solutions in clinical settings [6]